Low adoption of recommended biomarker testing in NSCLC and CRC and inappropriate treatment selection for patients with these cancers are increasingly highlighted in prominent publications

Gastroenterology Report

June 3, 2020

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

Cetuximab and panitumumab, as the highly effective antibodies targeting EGFR, have clinical activity in the patients with metastatic CRC…

Read more

JCO Precision Oncology

December 6, 2019

Genomic Profiling for KRASNRASBRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer

Genomic testing is recognized in national guidelines as essential to guide appropriate therapy selection in metastatic colorectal cancer…

Read more


October 24, 2019

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival in patients with metastatic colorectal cancer with the BRAF V600E mutation…

Read more

World J Gastrointest Oncol

April 15, 2019

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas

While the role of HER2 as a prognostic biomarker in CRC remains uncertain, its relevance as a therapeutic target has been established…

Read more

Clinical Cancer Research

December 15, 2015

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis…

Read more

Journal of Clinical Oncology

May 25, 2020

A retrospective three-year analysis using real-world data on uptake of broad-based NextGen sequencing panels in community oncology practices

There are over 100 FDA approved targeted therapies across 15 cancer types, offering improved outcomes over existing therapies. However, many of these require genetic testing, for example, advanced non-small cell…

Read more

National Comprehensive Cancer Network

February 11, 2020

NCCN Guidelines Version 3

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care. The NCCN Guidelines® currently…

Read more

Annals of Oncology

May 1, 2019

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitors are…

Read more

Clinical Cancer Research

April 15, 2019

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended…

Read more

Journal of Thoracic Oncology

June 1, 2018

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical benefit has been less frequently observed in patients whose tumors harbor EGFR mutations compared to EGFR wild-type patients. Our single-center…

Read more

Clinical Lung Cancer

April 13, 2017

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

National guidelines have advocated broad molecular profiling as a part of the standard diagnostic evaluation for advanced non–small cell lung cancer (NSCLC), with the goal of identifying driver mutations for…

Read more

Clinical Cancer Research

May 25, 2016

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

PD-1 inhibitors are established agents in the management of non–small cell lung cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine the activity of PD-1/PD-L1 inhibitors…

Read more